• Founded: 2018
  • Location: Seattle, WA
  • Employee range: 11 - 50
  • Clinical stage: Clin2
  • Therapy area: RSV
  • Drug types: VAC, INF
  • Lead product: IVX-A12
  • Product link: https://icosavax.com/pipeline/
  • Funding: $67.8M stock May 2023; $209M IPO Jul 2021; $100M B Apr 2021; $51M A Oct 2019



job board

Short description:

Vaccines, VLP

Drug notes:

IVX-121 Clin2 RSV; undisclosed RD COVID-19; undisclosed RD influenza

Long description:

Icosavax is developing vaccines to protect older adults against multiple respiratory viruses. Icosavax’s approach centers around their virus-like particles (VLPs) - these VLPs are designed to mimic the structure of viruses and therefore the body sees the VLPs as a virus, as opposed to soluble antigens that are being used by mRNA-derived vaccines. Therefore, Icosavax hopes the VLPs will empower a better immune response that is stronger and more durable. Currently, Icosavax is progressing multiple assets including a Phase 2 clinical trials in progress for the prevention of RSV and hMPV.


© 2024 Work In Biotech LLC
Personal data

Terms of Service

Privacy Policy

Contact: recruit@workinbiotech.com